Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 3292749

Bone mineral content: data analysis.

F Mimouni·R C Tsang
View original source ↗Export metadata ↓

Abstract

We reviewed the literature related to intrauterine bone mineral content (BMC) curves and the expression of BMC measurements in infants. From this review, it appears that the curves developed by Greer and by Minton for the radius are extremely similar and that both should be used as the reference curve. It also appears that expression of assessment results in terms of BMC and bone width (BW) permits an evaluation of growth of bone mass versus growth of size of the bone scanned. Although the BMC/BW ratio might be a useful but unproved conceptual adjunct, expression of photon absorptiometry results in terms of the BMC/BW ratio alone does not confer any specific advantage and theoretically could mask important specific information about bone mass and size.

Explore related subjects

Bone DevelopmentBone and BonesChildHumansInfantInfant, NewbornMineralsRadionuclide ImagingReference StandardsReference ValuesJournal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, P.H.S.Review

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

F Mimouni, R C Tsang. 1988. Bone mineral content: data analysis.. https://doi.org/10.1016/s0022-3476(88)80608-5

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1998

Bone growth after lengthening of the lower limb in children.

Femoral and tibial growth was studied in 6 children undergoing a femoral lengthening and 28 children a tibial lengthening. Growth of both femurs and tibiae was evaluated for 3 years both before and after the procedure. No significant growth disturbance was noted in femoral lengthenings of 14%. However, growth variations were constant after tibial lengthening of 18% on the average and could be correlated to the amount of lengthening. The consequences of these changes are limited in terms of final limb length because overgrowth of the femur often compensates for growth retardation of the tibia when tibial lengthening is less than 18%. Experimental and clinical studies assert that lengthenings of more than 30% can result in significant and definite growth retardation of the lengthened bone.

Bone Development↗
PubMed1998

Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormone-related peptide-(1-36) in humans: potential as an anabolic therapy for osteoporosis.

PTH administration increases bone mass in rodents and in humans. PTH-related protein (PTHrP) binds to and signals via the skeletal PTH receptor. Administration of PTHrP on a once daily basis increases bone mineral content in rats. In humans, PTHrP-(1-36) is equipotent to PTH-(1-34) and is active when administered s.c. These findings suggest that PTHrP might have therapeutic benefit in the treatment of osteoporosis. In this study, 13 postmenopausal estrogen-deficient women received a single daily s.c. dose of PTHrP-(1-36) for a 14-day period to determine whether PTHrP-(1-36) 1) could be given in doses that do not alter systemic mineral homeostasis, but increase markers of bone turnover; and 2) is tolerated without adverse effects. Daily s.c. PTHrP-(1-36) administration caused no significant changes in serum calcium or phosphorus concentrations, fractional calcium excretion, the tubular maximum for phosphorus, fractional calcium excretion, or plasma 1,25-dihydroxyvitamin D concentrations. Nephrogenous cAMP and endogenous PTH-(1-84) declined. Importantly, markers of bone formation trended upward, as reported in subjects treated with PTH. In marked contrast to findings in PTH-treated subjects, in PTHrP-treated subjects, markers of bone resorption declined in a highly significant fashion. These observations indicate that PTHrP-(1-36) treatment uncouples bone formation from resorption, in favor of formation. This uncoupling, if it were to continue over the longer term, would predict that PTHrP-(1-36) might be a potent anabolic therapeutic agent for osteoporosis.

Bone Development↗